# Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy

Study · id `cardio:ct-nct07052799` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07052799](<https://clinicaltrials.gov/study/NCT07052799>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07052799

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2514 participants.

## Technical summary

Registry record NCT07052799. Randomized; quadruple masking; primary purpose prevention. Start 2026-02-10 (actual); primary completion 2030-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 2514 participants (planned count; ClinicalTrials.gov record NCT07052799, source copy `cardio:ctgov-nct07052799-2026-03-18`, retrieved 2026-10-26)
- Started: 2026-02-10 (actual) (ClinicalTrials.gov record NCT07052799, source copy `cardio:ctgov-nct07052799-2026-03-18`, retrieved 2026-10-26)
- Primary completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07052799, source copy `cardio:ctgov-nct07052799-2026-03-18`, retrieved 2026-10-26)
- Completion: 2031-12-31 (anticipated) (ClinicalTrials.gov record NCT07052799, source copy `cardio:ctgov-nct07052799-2026-03-18`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT07052799, source copy `cardio:ctgov-nct07052799-2026-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07052799-2026-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
- Condition: Myocardial Infarction (MI)
- Condition: Cardiovascular Events
- Condition: Post Polypectomy Bleeding in Antiplatelet Patients
- Intervention (Drug): Aspirin 80mg
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)

## Provenance

Content hash: b6ecf98a49a10d4f80b87592a8be44719a6950b0b5abaaf3021d797fdd6ed91d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
